Ionis Pharmaceuticals has concluded enrolment in the pivotal cohort (Cohort 1) of its Phase III REVEAL study of obudanersen (ION582) as an investigational ribonucleic acid (RNA)-t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results